HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E.
Ontology highlight
ABSTRACT: Rationale: Melanoma is an aggressive tumor of the skin and drug resistance is still a major problem in melanoma therapy. Novel targets and effective agents to overcome drug resistant melanoma are urgently needed in clinical therapy. Methods: Gene Expression Omnibus (GEO) database analysis, pathway enrichment analysis, and survival rate analysis were utilized to identify a candidate target. An anchorage-independent cell growth assay, flow cytometry, Western blot, and a xenograft mouse model were used to study the function of Aurora kinase B (AURKB) in both drug-sensitive and drug-resistant melanoma. Next, HI-511, a novel dual-target inhibitor targeting both AURKB and BRAF V600E, was designed and examined by an in vitro kinase assay. Methods as indicated above in additio
SUBMITTER: Chang X
PROVIDER: S-EPMC7449901 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA